SHIRE PLC: Pre-quarterly Results 
April 11, 2014 - Shire (LSE: SHP, NASDAQ: SHPG) provides information in
respect of certain factors that should be considered when updating models
ahead of Shire's Q1 2014 results. 
Foreign Exchange 
Average exchange rates for Q1 2014 were $1.66:£1.00, $1.37:€1.00
and $1.12:CHF1. Foreign exchange is not expected to have a material effect on
revenues in Shire's Q1 2014 results. 
Quarter average    Q1 2013  Q2 2013  Q3 2013  Q4 2013  Q1 2014
USD:£1               1.58     1.53     1.53     1.62     1.66
USD:€1               1.33     1.30     1.32     1.36     1.37
USD:CHF1             1.09     1.06     1.07     1.10     1.12 
FX impact on          0%      -1%       0%       0%      -1%
YTD average rate Q1 2013  HY 2013  9m 2013  FY 2013  Q1 2014
USD:£1             1.58     1.55     1.55     1.56     1.66
USD:€1             1.33     1.31     1.31     1.33     1.37
USD:CHF1           1.09     1.07     1.07     1.08     1.12 
FX impact on        0%       0%       0%       0%      -1%
FX Ready Reckoner 
Currency            Impact on 2014 Full Year Guidance Non GAAP EPS
Pound Sterling 10 cents movement in average exchange rate for full year 
                      impacts EPS by approximately +/- 0%
Euro           10 cents movement in average exchange rate for full year 
                      impacts EPS by approximately +/- 2%
Swiss Franc    10 cents movement in average exchange rate for full year 
                      impacts EPS by approximately +/- 0% 
Details of our outlook including full year Non GAAP EPS for 2014
and the calculation of Non GAAP EPS are set out in our full Year 2013 results
presentation and press release which can be found at: 
Number of Shares 
The basic weighted number of shares (WANS) in issue during Q1 2014
was 584.3m (Q1 2013: 551.5m). 
As of December 31, 2013 the aggregate principal amount of our $1,099,050,000
Convertible Bonds due 2014 ("Bonds") had been voluntarily converted by bond
holders into 33,806,464 fully paid Ordinary Shares. The remaining outstanding
Bonds in an aggregate principal amount of $950,000 were redeemed on December
27, 2013. In Q1 2014 no bonds which were convertible into Shire ordinary
shares remained outstanding, and therefore no additional shares related to the
convertible bonds will be included in diluted WANS in Q1 2014. 
in millions             Q1 2013 Q2 2013 Q3 2013 Q4 2013   Q1 2014 
Basic WANS (1)           551.5   549.6   548.4   558.0     584.3
Share based employee      3.8     2.6     3.5     4.9      4-6m
Convertible Bonds        33.6    33.8    33.8    27.7        0
Diluted WANS             588.9   586.0   585.7   590.6 
Note: YTD Diluted WANS   588.9   587.5   587.5   590.3
(1) Excludes shares purchased by the Employee Benefit Trust and
under the share buy-back program, presented by Shire as treasury stock. 
The 2013 numbers in table above have been recast to exclude the
DERMAGRAFT business as discontinued operations. 
Discontinued Operations 
On January 17, 2014 Shire announced that it had sold its
DERMAGRAFT® [1] business, comprising the key operating assets relating to the
development, manufacture and sale of the DERMAGRAFT product, to Organogenesis
Inc. ("Organogenesis"). On February 4, 2014 Shire released historical income
statements for 2012 and the nine months ended September 30, 2013, recast to
show the impact of DERMAGRAFT operations as discontinued, which can be found
On February 13, 2014 Shire released Full Year 2013 results which
reclassified the DERMAGRAFT business as "discontinued operations" for the
years ended December 31, 2013 and 2012 and Q4 2013 and 2012, excluding the
impact of the DERMAGRAFT business from continuing operations. These results
can be found at: 
Acquisition of ViroPharma Incorporated ("ViroPharma") 
On January 24, 2014, Shire completed the acquisition of all of the
outstanding shares of ViroPharma. Shire's Q1 2014 results will include the
results of ViroPharma from January 24, 2014. 
Total consideration, including amounts payable in respect of stock
options and warrants over ViroPharma's common stock, was approximately $4.0
Disposal of CALCICHEW® 
From January 1, 2014 Shire has not recorded product sales for CALCICHEW (Q1
2013 product sales $7 million, full year 2013 $34 million). In Q1 2014 Shire
transferred the marketing authorisations for the CALCICHEW [2] range of
products in the UK and Ireland to Takeda. 
Investor news flow 
Further investor news issued during Q1 2014 can be found at: 
Statements included in this release that are not historical facts are
forward-looking statements. Forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire's results could be materially
adversely affected. The risks and uncertainties include, but are not limited
to, that: 
- Shire's products may not be a commercial success; 
- revenues from ADDERALL XR are subject to generic erosion and revenues from
INTUNIV will become subject to generic competition starting in December 2014; 
- the failure to obtain and maintain reimbursement, or an adequate level of
reimbursement, by third-party payors in a timely manner for Shire's products
may impact future revenues, financial condition and results of operations; 
- Shire conducts its own manufacturing operations for certain of its Rare
Diseases products and is reliant on third party contractors to manufacture
other products and to provide goods and services. Some of Shire's products or
ingredients are only available from a single approved source for manufacture.
Any disruption to the supply chain for any of Shire's products may result in
Shire being unable to continue marketing or developing a product or may result
in Shire being unable to do so on a commercially viable basis for some period
of time. 
- the development, approval and manufacturing of Shire's products is subject
to extensive oversight by various regulatory agencies and regulatory approvals
or interventions associated with changes to manufacturing sites, ingredients
or manufacturing processes could lead to significant delays, increase in
operating costs, lost product sales, an interruption of research activities or
the delay of new product launches; 
- the actions of certain customers could affect Shire's ability to sell or
market products profitably. Fluctuations in buying or distribution patterns by
such customers can adversely impact Shire's revenues, financial conditions or
results of operations; 
- investigations or enforcement action by regulatory authorities or law
enforcement agencies relating to Shire's activities in the highly regulated
markets in which it operates may result in the distraction of senior
management, significant legal costs and the payment of substantial
compensation or fines; 
- adverse outcomes in legal matters and other disputes, including Shire's
ability to enforce and defend patents and other intellectual property rights
required for its business, could have a material adverse effect on Shire's
revenues, financial condition or results of operations; 
- Shire faces intense competition for highly qualified personnel from other
companies, academic institutions, government entities and other organizations.
Shire is undergoing a corporate reorganization and the consequent uncertainty
could adversely impact Shire's ability to attract and/or retain the highly
skilled personnel needed for Shire to meet its strategic objectives; 
- failure to achieve Shire's strategic objectives with respect to the
acquisition of ViroPharma Incorporated may adversely affect Shire's financial
condition and results of operations; 
and other risks and uncertainties detailed from time to time in Shire's
filings with the US Securities and Exchange Commission, including its most
recent Annual Report on Form 10-K. 
For further information please contact: 
Investor Relations 
Jeff Poulton
+1 781 482 0945 
Eric Rojas
+1 781 482 0999 
Sarah Elton-Farr
+44 1256 894157 
Notes to editors 
Shire enables people with life-altering conditions to lead better lives. 
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs. 
We provide treatments in Neuroscience, Rare Diseases,
Gastrointestinal and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas. 
[1] DERMAGRAFT® is a trade mark of Organogenesis. 
[2] CALCICHEW® is a trade mark of Takeda. 
-0- Apr/15/2014 11:55 GMT
Press spacebar to pause and continue. Press esc to stop.